• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Rhythm Pharmaceuticals Inc. (Amendment)

    4/30/24 7:31:21 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RYTM alert in real time by email
    SC 13D/A 1 nea13-rhythm_18827.htm NEW ENTERPRISE ASSOCIATES 13, LP (RHYTHM PHARMACEUTICALS) - SCHEDULE 13D/A(#2E) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Rhythm Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, $.001 par value

    (Title of Class of Securities)

    76243J105

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    April 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 76243J105

    13D Page 2 of 7 Pages    

     

     

    Item 1.Security and Issuer.

     

    This Amendment No. 2 to Schedule 13D amends and supplements the Schedule 13D originally filed on October 13, 2017, and Amendment No. 1 filed on March 29, 2023, and relates to the common stock, $.001 par value (the “Common Stock”) of Rhythm Pharmaceuticals, Inc. (the “Issuer”) having its principal executive office at 222 Berkeley Street, 12th Floor, Boston, MA 02116.

     

    Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (and Amendment No. 1 thereto).

     

     

     

    Item 2.Identity and Background.

     

    This statement is being filed by:

     

    (a) New Enterprise Associates 13, L.P. (“NEA 13”); NEA Partners 13, L.P. (“NEA Partners 13”), which is the sole general partner of NEA 13; and NEA 13 GP, LTD (“NEA 13 LTD” and together with NEA Partners 13, the “Control Entities”), which is the sole general partner of NEA Partners 13; and

     

    (b) Forest Baskett (“Baskett”), Patrick J. Kerins (“Kerins”) and Scott D. Sandell (“Sandell”) (together, the “Directors”). The Directors are the directors of NEA 13 LTD.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 13, each Control Entity, Sandell and Kerins is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025.

     

    The principal business of NEA 13 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 13 is to act as the sole general partner of NEA 13. The principal business of NEA 13 LTD is to act as the sole general partner of NEA Partners 13. The principal business of each of the Directors is to manage the Control Entities, NEA 13 and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 13 and NEA Partners 13 are exempted limited partnerships organized under the laws of the Cayman Islands. NEA 13 LTD is an exempted company organized under the laws of the Cayman Islands. Each of the Directors is a United States citizen.

     

     

     

     

     

    CUSIP No. 76243J105

    13D Page 3 of 7 Pages    

      

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    Not applicable.

     

     

     

    Item 4.Purpose of Transaction.

     

    Not applicable.

     

     

    Item 5.Interest in Securities of the Issuer.

     

     As of November 1, 2023, each of the Reporting Persons ceased to beneficially own five percent (5%) or more of the Issuer’s Common Stock. This Amendment No. 2 was triggered solely due to a change in the number of outstanding shares of the Issuer’s Common Stock.

     

     

     

    Item 6.Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

     

    Not applicable.

     

     

    Item 7.Material to be Filed as Exhibits.

     

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

    CUSIP No. 76243J105

    13D Page 4 of 7 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 30th day of April, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 13, L.P.

     

    By:

    NEA PARTNERS 13, L.P.

    General Partner

     

    By:

    NEA 13 GP, LTD

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Director 

     

    NEA PARTNERS 13, L.P.

     

    By:NEA 13 GP, LTD
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Director 

     

      

    NEA 13 GP, LTD

     

    By:          *                                

    Scott D. Sandell

    Director

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Patrick J. Kerins

     

     

                     *                        

    Scott D. Sandell

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

    This Amendment No. 2 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     
     

     

    CUSIP No. 76243J105

    13D Page 5 of 7 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Rhythm Pharmaceuticals, Inc.

     

    EXECUTED this 30th day of April, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 13, L.P.

     

    By:

    NEA PARTNERS 13, L.P.

    General Partner

     

    By:

    NEA 13 GP, LTD

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Director 

     

    NEA PARTNERS 13, L.P.

     

    By:NEA 13 GP, LTD
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Director 

     

      

    NEA 13 GP, LTD

     

    By:          *                                

    Scott D. Sandell

    Director

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Patrick J. Kerins

     

     

                     *                        

    Scott D. Sandell

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

    This Agreement relating to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

    CUSIP No. 76243J105

    13D Page 6 of 7 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

     

     

    /s/ Peter J. Barris  
    Peter J. Barris  
       
    /s/ Forest Baskett  
    Forest Baskett  
       
    /s/ Ali Behbahani  
    Ali Behbahani  
       
    /s/ Ronald D. Bernal  
    Ronald D. Bernal  
       
    /s/ Ann Bordetsky  
    Ann Bordetsky  
       
    /s/ Carmen Chang  
    Carmen Chang  
       
    /s/ Philip Chopin  
    Philip Chopin  
       
    /s/ Anthony A. Florence, Jr.  
    Anthony A. Florence, Jr.  
       
    /s/ Jonathan Golden  
    Jonathan Golden  
       
    /s/ Scott Gottlieb  
    Scott Gottlieb  

     

                         

     

     

     

    CUSIP No. 76243J105

    13D Page 7 of 7 Pages    

     

     

     

     

    /s/ Mark Hawkins  
    Mark Hawkins  
       
    /s/ Jeffrey R. Immelt  
    Jeffrey R. Immelt  
       
    /s/ Aaron Jacobson  
    Aaron Jacobson  
       
    /s/ Patrick J. Kerins  
    Patrick J. Kerins  
       
    /s/ Hilarie Koplow-McAdams  
    Hilarie Koplow-McAdams  
       
    /s/ Vanessa Larco  
    Vanessa Larco  
       
    /s/ Julio C. Lopez  
    Julio C. Lopez  
       
    /s/ Tiffany Le  
    Tiffany Le  
       
    /s/ Mohamad H. Makhzoumi  
    Mohamad H. Makhzoumi  
       
    /s/ Edward T. Mathers  
    Edward T. Mathers  
       
    /s/ Gregory Papadopoulos  
    Gregory Papadopoulos  
       
    /s/ Kavita Patel  
    Kavita Patel  
       
    /s/ Scott D. Sandell  
    Scott D. Sandell  
       
    /s/ A. Brooke Seawell  
    A. Brooke Seawell  
     
    /s/ Peter Sonsini  

    Peter Sonsini

     
       
    /s/ Melissa Taunton  
    Melissa Taunton  
       
    /s/ Paul E. Walker  
    Paul E. Walker  
       
    /s/ Rick Yang  
    Rick Yang  

     

     


     

      

    Get the next $RYTM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RYTM

    DatePrice TargetRatingAnalyst
    7/14/2025$130.00Mkt Perform → Mkt Outperform
    Citizens JMP
    7/10/2025$97.00Buy
    Goldman
    7/7/2025$88.00Outperform
    Leerink Partners
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    12/20/2024$76.00Outperform
    Oppenheimer
    10/21/2024$70.00Buy
    Guggenheim
    More analyst ratings

    $RYTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

      - Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced data from three new presentations on the Company's clinical programs for acquired hypothalamic obesity at the Endocrine Society's Annual Meeting (ENDO 2025) taking place July 12-15 in Sa

      7/12/25 6:00:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

      BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ("Rhythm"), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced the pricing of its upsized public offering of 2,058,824 shares of its common stock at a public offering price of $85.00 per share. In addition, Rhythm also granted the underwriters a 30-day option to purchase up to an additional 308,823 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $175 million, before deducting un

      7/10/25 6:21:38 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

      BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ("Rhythm"), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of $150 million of its common stock. All securities in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. Morgan Stanley, BofA Securities, Stifel and Wells Fargo Securities are acting as joint book-runnin

      7/9/25 4:16:30 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rhythm Pharmaceuticals upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Rhythm Pharmaceuticals from Mkt Perform to Mkt Outperform and set a new price target of $130.00

      7/14/25 8:28:35 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Rhythm Pharmaceuticals with a new price target

      Goldman initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $97.00

      7/10/25 8:59:57 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Rhythm Pharmaceuticals with a new price target

      Leerink Partners initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $88.00

      7/7/25 8:21:59 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    SEC Filings

    See more
    • Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      7/11/25 7:00:51 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Rhythm Pharmaceuticals Inc.

      424B5 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      7/10/25 4:50:17 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Rhythm Pharmaceuticals Inc.

      424B5 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      7/9/25 5:06:28 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Smith Hunter C exercised 42,120 shares at a strike of $6.88 and sold $3,389,756 worth of shares (42,120 units at $80.48) (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      7/11/25 4:31:09 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Technical Officer Shulman Joseph exercised 7,969 shares at a strike of $6.80 and sold $619,851 worth of shares (7,969 units at $77.78) (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      7/11/25 4:30:51 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corporate Controller & CAO German Christopher Paul exercised 2,850 shares at a strike of $27.29 and sold $308,217 worth of shares (3,817 units at $80.75), decreasing direct ownership by 51% to 922 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      7/11/25 4:30:31 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

      SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 9:50:26 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 5:46:11 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/12/24 5:23:38 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Financials

    Live finance-specific insights

    See more
    • Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

      -- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reductions in bivamelagon trial were consistent with BMI reductions achieved by setmelanotide in past trials in similar patient populations -- -- Patients in both 600mg and 400mg cohorts achieved mean reduction of -2.8 points in most hunger scores -- -- Limited instances of localized hyperpigmentation observed -- -- Rhythm to request End-of-Phase 2 meeting with U.S. FDA in order to pursue registrational path for bivamelagon in acquired hypothalamic obesity -- -- Company to host conference cal

      7/9/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

      BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Wednesday, July 9, 2025 at 8:00 a.m. ET to disclose topline results from the randomized, placebo-controlled portion of the Phase 2 trial evaluating bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. Conference Call InformationRhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,

      7/8/25 4:01:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

      BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience

      7/8/24 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

      BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade

      10/6/22 4:02:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wren Appoints Bart Henderson as Chief Executive Officer

      Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired

      3/4/22 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care